MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2018 financial results on Thursday, November 1, 2018. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, […]
Other News
Geneva Health Solutions Launches Geneva University
NEW YORK–(BUSINESS WIRE)–Geneva Health Solutions (GHS), the leading cloud-based technology platform and service for managing data from implantable cardiac devices, has formalized its internal training systems by launching Geneva University, a business unit within GHS. Geneva University will be focused on the continuous improvement of all clinical and administrative processes. “Implantable […]
Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares
MONTRÉAL, Oct. 11, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced today the closing of its previously announced underwritten public offering […]
CHF Solutions Initiates Strategic Collaboration with NI Medical on Management of Fluid Overloaded Patients
EDEN PRAIRIE, Minn., Oct. 11, 2018 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (Nasdaq: CHFS) announced today that it has entered into a collaboration agreement with NI Medical to explore potential clinical synergies between the company’s Aquadex FlexFlow® System and NI Medical’s NICaS Hemodynamic Navigator to assess patient’s fluid volume status and […]
Transseptal Solutions Announces FDA Clearance of Its Novel Transseptal Access System for Transseptal Puncture and Left Atrial Navigation
NETANYA, Israel, October 11, 2018 /PRNewswire/ — Transseptal Solutions Ltd., developer of an innovative Transseptal Access System with a novel approach of transseptal puncture and left atrial navigation to introduce various cardiovascular catheters into the left heart chambers, announced today that the company has received FDA 510(k) clearance for the TSP Crosser[TM] Transseptal Access System. […]
Heart Center Dresden to Be First Commercial Clinical Site for Imricor
MINNEAPOLIS–(BUSINESS WIRE)–Imricor announced today that it signed its first commercialization contract for the Advantage-MR EP Recorder/Stimulator System and supporting Vision-MR devices1 with the Heart Center Dresden in Germany. This agreement places the Heart Center Dresden at the forefront of clinical advancement for MRI-guided cardiac ablations and establishes the hospital as a […]
Veryan Medical’s BioMimics 3D receives PMA approval
04 October 2018: Veryan Medical Ltd (Horsham, UK) today announced that the Company has received Premarket Approval (PMA) for the BioMimics 3D Vascular Stent System from the U.S. Food & Drug Administration (FDA). The device is approved for the treatment of symptomatic de novo or restenotic lesions in the native […]
Orchestra BioMed™ Strengthens Operations, R&D and Pharmaceutical Development Expertise with Key Leadership Team Additions
NEW HOPE, Pa., Oct. 10, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions, announced today that it has appointed three key members to its management team. Joining the […]
iRhythm Technologies to Report Third Quarter Financial Results on October 30, 2018
SAN FRANCISCO, Oct. 09, 2018 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the third quarter 2018 after the close of trading on Tuesday, October 30, 2018. The company’s […]
Cardialen Closes $17 Million Series B Financing for Heart Rhythm Therapy
MINNEAPOLIS–(BUSINESS WIRE)–Cardialen, Inc., a medical device company developing a low-energy implantable defibrillation therapy designed to more gently restore normal heart rhythm, announced today the closing of a $17 million Series B investment led by RiverVest Venture Partners, along with Qiming Venture Partners, HBM Healthcare Investments and Cultivation Capital. The financing will […]



